Terms: = Ovarian cancer AND CCND2, KIAK0002, 894, ENSG00000118971, P30279, MGC102758 AND Treatment
18 results:
1. Development of an Automatic Rule-Based Algorithm for the Detection of ovarian cancer Recurrence From Electronic Health Records.
Lee S; Kim JH; Ha HI; Lim MC; Cho H
JCO Clin Cancer Inform; 2024 Mar; 8():e2300150. PubMed ID: 38442323
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials.
Huang D; Ke L; Cui H; Li S; Sun F
BMC Womens Health; 2024 Jan; 24(1):34. PubMed ID: 38218775
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of Effectiveness as well as Advantages and Disadvantages of Different Dimensions of Hysterosalpingo-Contrast Sonography for Diagnosis of Lesions Associated with Female Infertility.
Pei R
Comput Math Methods Med; 2022; 2022():7508880. PubMed ID: 36164612
[TBL] [Abstract] [Full Text] [Related]
4. Early drug development in solid tumours: analysis of National cancer Institute-sponsored phase 1 trials.
Chihara D; Lin R; Flowers CR; Finnigan SR; Cordes LM; Fukuda Y; Huang EP; Rubinstein LV; Nastoupil LJ; Ivy SP; Doroshow JH; Takebe N
Lancet; 2022 Aug; 400(10351):512-521. PubMed ID: 35964611
[TBL] [Abstract] [Full Text] [Related]
5. Is adjuvant chemotherapy necessary for young women with early-stage epithelial ovarian cancer who have undergone fertility-sparing surgery?: a multicenter retrospective analysis.
Ikeda Y; Yoshihara M; Yoshikawa N; Yokoi A; Tamauchi S; Nishino K; Niimi K; Kajiyama H
BMC Womens Health; 2022 Mar; 22(1):80. PubMed ID: 35313889
[TBL] [Abstract] [Full Text] [Related]
6. The flavonoid, kaempferol-3-O-apiofuranosyl-7-O-rhamnopyranosyl, as a potential therapeutic agent for breast cancer with a promoting effect on ovarian function.
Harrath AH; Jalouli M; Oueslati MH; Farah MA; Feriani A; Aldahmash W; Aldawood N; Al-Anazi K; Falodah F; Swelum A; Alwasel S
Phytother Res; 2021 Nov; 35(11):6170-6180. PubMed ID: 33908658
[TBL] [Abstract] [Full Text] [Related]
7. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Piccart M; van 't Veer LJ; Poncet C; Lopes Cardozo JMN; Delaloge S; Pierga JY; Vuylsteke P; Brain E; Vrijaldenhoven S; Neijenhuis PA; Causeret S; Smilde TJ; Viale G; Glas AM; Delorenzi M; Sotiriou C; Rubio IT; Kümmel S; Zoppoli G; Thompson AM; Matos E; Zaman K; Hilbers F; Fumagalli D; Ravdin P; Knox S; Tryfonidis K; Peric A; Meulemans B; Bogaerts J; Cardoso F; Rutgers EJT
Lancet Oncol; 2021 Apr; 22(4):476-488. PubMed ID: 33721561
[TBL] [Abstract] [Full Text] [Related]
8. Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.
Hassan MK; Waly AA; Elsayed W; Keshk S; Allam WR; El-Khamisy SF
Sci Rep; 2021 Jan; 11(1):562. PubMed ID: 33436648
[TBL] [Abstract] [Full Text] [Related]
9. Identification of Potential Biomarkers and Metabolic Profiling of Serum in ovarian cancer Patients Using UPLC/Q-TOF MS.
Yang W; Mu T; Jiang J; Sun Q; Hou X; Sun Y; Zhong L; Wang C; Sun C
Cell Physiol Biochem; 2018; 51(3):1134-1148. PubMed ID: 30476914
[TBL] [Abstract] [Full Text] [Related]
10. Statin as a Combined Therapy for Advanced-Stage ovarian cancer: A Propensity Score Matched Analysis.
Chen HY; Wang Q; Xu QH; Yan L; Gao XF; Lu YH; Wang L
Biomed Res Int; 2016; 2016():9125238. PubMed ID: 27975064
[No Abstract] [Full Text] [Related]
11. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
[TBL] [Abstract] [Full Text] [Related]
12. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract] [Full Text] [Related]
13. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
Burger RA; Brady MF; Bookman MA; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente M; Fleming GF; Lim PC; Rubin SC; Katsumata N; Liang SX
J Clin Oncol; 2014 Apr; 32(12):1210-7. PubMed ID: 24637999
[TBL] [Abstract] [Full Text] [Related]
14. Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment.
Srisuttayasathien M; Khemapech N
Asian Pac J Cancer Prev; 2013; 14(12):7669-74. PubMed ID: 24460351
[TBL] [Abstract] [Full Text] [Related]
15. HIF-1α induced by β-elemene protects human osteosarcoma cells from undergoing apoptosis.
Liang D; Yang M; Guo B; Yang L; Cao J; Zhang X
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1865-77. PubMed ID: 22736026
[TBL] [Abstract] [Full Text] [Related]
16. Mature and immature teratomas: results of the first paediatric Italian study.
Lo Curto M; D'Angelo P; Cecchetto G; Klersy C; Dall'Igna P; Federico A; Siracusa F; Alaggio R; Bernini G; Conte M; De Laurentis T; Di Cataldo A; Inserra A; Santoro N; Tamaro P; Indolfi P
Pediatr Surg Int; 2007 Apr; 23(4):315-22. PubMed ID: 17333214
[TBL] [Abstract] [Full Text] [Related]
17. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.
Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):480-6. PubMed ID: 17089122
[TBL] [Abstract] [Full Text] [Related]
18. Complementary health practitioners' attitudes, practices and knowledge related to women's cancers.
Gray RE; Fitch M; Saunders PR; Wilkinson A; Ross CP; Franssen E; Caverhill K
Cancer Prev Control; 1999 Feb; 3(1):77-82. PubMed ID: 10474756
[TBL] [Abstract] [Full Text] [Related]
